New hope for tough Behcet's: drug shows promise in small trial
NCT ID NCT07080346
First seen Jan 07, 2026 · Last updated May 17, 2026 · Updated 24 times
Summary
This study tested the drug upadacitinib in 27 adults with Behcet's syndrome that did not improve with standard treatments. The goal was to see if the drug could reduce symptoms and prevent new disease activity. Results showed that many patients experienced improvement, but the drug is not a cure and long-term management is still needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BEHCET SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Department of Rheumatology and Immunology, Peking University People's Hospital
Beijing, Beijing Municipality, 100044, China
Conditions
Explore the condition pages connected to this study.